These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3304613)

  • 1. Quality of life measurement in testicular cancer patients.
    Herr HW
    Cancer; 1987 Sep; 60(6):1412-4. PubMed ID: 3304613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.
    Bosl GJ; Geller NL; Bajorin D; Leitner SP; Yagoda A; Golbey RB; Scher H; Vogelzang NJ; Auman J; Carey R
    J Clin Oncol; 1988 Aug; 6(8):1231-8. PubMed ID: 2457657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).
    Fosså SD; de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Cook P; de Prijck L; Stenning S; Aaronson NK; Bottomley A; Collette L; ;
    J Clin Oncol; 2003 Mar; 21(6):1107-18. PubMed ID: 12637478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors.
    Bosl GJ; Geller NL; Vogelzang NJ; Carey R; Auman J; Whitmore WF; Herr H; Morse M; Sogani P; Chan E
    J Clin Oncol; 1987 Mar; 5(3):436-40. PubMed ID: 2434627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor prognosis germ cell tumors of the testes: improved results with high dose regimens.
    Ozols RF
    Prog Clin Biol Res; 1988; 269():419-27. PubMed ID: 2455910
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
    de Wit R; Stoter G; Kaye SB; Sleijfer DT; Jones WG; ten Bokkel Huinink WW; Rea LA; Collette L; Sylvester R
    J Clin Oncol; 1997 May; 15(5):1837-43. PubMed ID: 9164193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
    Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
    Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity comparisons between two chemotherapy regimens as adjuvant or salvage treatment in nonseminomatous testicular cancer.
    Weiss RB; Stablein DM; Muggia FM; Einhorn LH; Golbey RB; DeWys WD
    Cancer; 1988 Jul; 62(1):18-23. PubMed ID: 2454718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The chemotherapy of nonseminomatous testicular tumors].
    Tiuliandin SA; Bulanov AA; Titov DA; Sokolov AV; Sholokhov VN; Garin AM
    Urol Nefrol (Mosk); 1996; (2):26-9. PubMed ID: 8677548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients.
    Motzer RJ; Geller NL; Bosl GJ
    Cancer; 1990 Sep; 66(5):857-61. PubMed ID: 1696846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multivariate analysis of prognostic factors in disseminated non-seminomatous testicular cancer.
    Stoter G; Sylvester R; Sleijfer DT; ten Bokkel Huinink WW; Kaye SB; Jones WG; van Oosterom AT; Vendrik CP; Spaander P; de Pauw M
    Prog Clin Biol Res; 1988; 269():381-93. PubMed ID: 2455909
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
    Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
    J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term complications of chemotherapy for germ cell tumours.
    Chaudhary UB; Haldas JR
    Drugs; 2003; 63(15):1565-77. PubMed ID: 12887263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [BEP (bleomycin, etoposide, cisplatin) therapy for testicular tumors].
    Mori Y; Shima H; Ihara H; Yabumoto H; Iwasaki A; Yoshioka M; Ikoma F
    Hinyokika Kiyo; 1992 Oct; 38(10):1139-42. PubMed ID: 1282774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testicular cancer: a longitudinal pilot study on stress response symptoms and quality of life in couples before and after chemotherapy.
    Tuinman MA; Hoekstra HJ; Sleijfer DT; Fleer J; Vidrine DJ; Gritz ER; Hoekstra-Weebers JE
    Support Care Cancer; 2007 Mar; 15(3):279-86. PubMed ID: 16944218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of high risk patients with advanced testis cancer: National Cancer Institute approach.
    Ozols RF; Ihde DC; Linehan WM; Young RC
    Semin Oncol; 1988 Aug; 15(4):335-8. PubMed ID: 2457255
    [No Abstract]   [Full Text] [Related]  

  • 18. Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma.
    Peckham MJ; Horwich A; Blackmore C; Hendry WF
    Cancer Treat Rep; 1985 May; 69(5):483-8. PubMed ID: 2408750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy.
    Lubberts S; Boer H; Altena R; Meijer C; van Roon AM; Zwart N; Oosting SF; Kamphuisen PW; Nuver J; Smit AJ; Mulder AB; Lefrandt JD; Gietema JA
    Eur J Cancer; 2016 Aug; 63():180-8. PubMed ID: 27322917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of disseminated germ cell tumors.
    Einhorn LH
    Cancer; 1987 Aug; 60(3 Suppl):570-3. PubMed ID: 2439185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.